Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886489 | 1.00 | HSD17B10 (0.55) | HSD17B10ALDH1A1TP53GAAMAPT | |
| SCHEMBL11715604 | 0.86 | SMN1; SMN2 (0.49) | ALDH1A1GAAMAPTNPC1RAB9A | |
| SCHEMBL11715589 | 0.86 | SMN1; SMN2 (0.49) | ALDH1A1GAAMAPTNPC1RAB9A | |
| SCHEMBL5404380 | 0.86 | MAPT (0.46) | HSD17B10ALDH1A1TP53MAPTNPC1 | |
| SCHEMBL5404383 | 0.86 | MAPT (0.46) | HSD17B10ALDH1A1TP53MAPTNPC1 | |
| SCHEMBL1717228 | 0.85 | MAPT (0.51) | HSD17B10ALDH1A1GAAMAPTNPC1 | |
| SCHEMBL1717226 | 0.85 | MAPT (0.51) | HSD17B10ALDH1A1GAAMAPTNPC1 | |
| SCHEMBL1974848 | 0.85 | MAPT (0.51) | HSD17B10ALDH1A1GAAMAPTNPC1 | |
| SCHEMBL11723450 | 0.85 | SMN1; SMN2 (0.54) | HSD17B10ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL11723465 | 0.85 | SMN1; SMN2 (0.54) | HSD17B10ALDH1A1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691854-B2 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-19 | — | — | US | disclosed |
| US-7199136-B2 | 1,4-dihydro-1,4-diphenylpyridine derivatives | BAYER HEALTHCARE AG (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20050165014-A1 | Antiinflammatory agents, neutrophil elastase inhibitors; chronic obstructive pulmonary diseases | BAYER HEALTHCARE AG | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165014-A1 | Antiinflammatory agents, neutrophil elastase inhibitors; chronic obstructive pulmonary diseases | SERPINB1, ELANE, MPO | HSD17B10 2446/4885ALDH1A1 395/4885TP53 4544/4885 |
| US-20070167406-A1 | Dihydropyridine derivatives for use as human neutrophil elastase inhibitors | SERPINB1, ELANE, MPO | HSD17B10 1774/4885ALDH1A1 400/4885TP53 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.